Insights

Innovative AI Platform Lantern Pharma's proprietary RADR AI platform offers advanced biomarker discovery, drug response prediction, and clinical trial design, presenting opportunities to partner with biopharma companies seeking cutting-edge computational tools to accelerate their research pipelines.

Global Expansion The recent launch of an AI center in India and expanded facilities highlight Lantern's commitment to industrializing its AI technology internationally, opening doors for regional collaborations and access to emerging oncology markets.

Focus on CNS Cancers Development of therapies targeting central nervous system cancers, including ATRT, creates potential sales channels with specialized neuro-oncology centers and institutions interested in innovative treatments for rare and aggressive tumors.

Strategic Funding & Growth With $60M in funding and ongoing revenue streams, Lantern is positioned for further clinical development and technology commercialization, offering opportunities for investors and partners in biotech innovation and biotech support services.

Upcoming Industry Engagements Participation in key events like the Glioblastoma Drug Development Summit and AI for Biology and Medicine symposium indicates active industry outreach, suitable for forming strategic alliances with research institutions and biotech firms.

Lantern Pharma Inc. (Nasdaq: LTRN) Tech Stack

Lantern Pharma Inc. (Nasdaq: LTRN) uses 8 technology products and services including Google Workspace, Twemoji, Lightbox, and more. Explore Lantern Pharma Inc. (Nasdaq: LTRN)'s tech stack below.

  • Google Workspace
    Email
  • Twemoji
    Font Scripts
  • Lightbox
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • HubSpot
    Marketing Automation
  • PWA
    Miscellaneous
  • Quantcast
    System Analytics & Monitoring
  • Bootstrap
    UI Frameworks

Media & News

Lantern Pharma Inc. (Nasdaq: LTRN)'s Email Address Formats

Lantern Pharma Inc. (Nasdaq: LTRN) uses at least 1 format(s):
Lantern Pharma Inc. (Nasdaq: LTRN) Email FormatsExamplePercentage
First@lanternpharma.comJohn@lanternpharma.com
91%
FirstL@lanternpharma.comJohnD@lanternpharma.com
4%
Last@lanternpharma.comDoe@lanternpharma.com
3%
FLast@lanternpharma.comJDoe@lanternpharma.com
2%

Frequently Asked Questions

Where is Lantern Pharma Inc. (Nasdaq: LTRN)'s headquarters located?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s main headquarters is located at 1920 Mckinney Avenue Dallas, Texas 75201 United States. The company has employees across 2 continents, including North AmericaEurope.

What is Lantern Pharma Inc. (Nasdaq: LTRN)'s official website and social media links?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s official website is lanternpharma.com and has social profiles on LinkedInCrunchbase.

What is Lantern Pharma Inc. (Nasdaq: LTRN)'s SIC code NAICS code?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Lantern Pharma Inc. (Nasdaq: LTRN) have currently?

Minus sign iconPlus sign icon
As of February 2026, Lantern Pharma Inc. (Nasdaq: LTRN) has approximately 25 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer, President And Board Member: P. S.Chief Financial Officer: D. M.Chief Scientific Officer: K. B.. Explore Lantern Pharma Inc. (Nasdaq: LTRN)'s employee directory with LeadIQ.

What industry does Lantern Pharma Inc. (Nasdaq: LTRN) belong to?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN) operates in the Biotechnology Research industry.

What technology does Lantern Pharma Inc. (Nasdaq: LTRN) use?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s tech stack includes Google WorkspaceTwemojiLightboxModernizrHubSpotPWAQuantcastBootstrap.

What is Lantern Pharma Inc. (Nasdaq: LTRN)'s email format?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN)'s email format typically follows the pattern of First@lanternpharma.com. Find more Lantern Pharma Inc. (Nasdaq: LTRN) email formats with LeadIQ.

How much funding has Lantern Pharma Inc. (Nasdaq: LTRN) raised to date?

Minus sign iconPlus sign icon
As of February 2026, Lantern Pharma Inc. (Nasdaq: LTRN) has raised $60M in funding. The last funding round occurred on Jan 14, 2021 for $60M.

When was Lantern Pharma Inc. (Nasdaq: LTRN) founded?

Minus sign iconPlus sign icon
Lantern Pharma Inc. (Nasdaq: LTRN) was founded in 2013.

Lantern Pharma Inc. (Nasdaq: LTRN)

Biotechnology ResearchTexas, United States11-50 Employees

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.

Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both of these central problems in oncology.

Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.

Section iconCompany Overview

Headquarters
1920 Mckinney Avenue Dallas, Texas 75201 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
11-50

Section iconFunding & Financials

  • $60M

    Lantern Pharma Inc. (Nasdaq: LTRN) has raised a total of $60M of funding over 7 rounds. Their latest funding round was raised on Jan 14, 2021 in the amount of $60M.

  • $10M$25M

    Lantern Pharma Inc. (Nasdaq: LTRN)'s revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $60M

    Lantern Pharma Inc. (Nasdaq: LTRN) has raised a total of $60M of funding over 7 rounds. Their latest funding round was raised on Jan 14, 2021 in the amount of $60M.

  • $10M$25M

    Lantern Pharma Inc. (Nasdaq: LTRN)'s revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.